


Product Name : ODM-207
Cat. No. : PC-38064
CAS No. : 1801503-93-4
Molecular Formula : C₂₂H₂₁N₃O₃
Molecular Weight : 375.428
Target : Bromodomain
Solubility : 10 mM in DMSO



Biological Activity

ODM-207 (ODM207) is a highly potent, selective and orally active **pan-BET** inhibitor with potent and broad antiproliferative effects.

ODM-207 effectively inhibits the proliferation of ER+ breast cancer cell lines by inducing cell cycle arrest in G₀/G₁-phase. ODM-207 suppresses the growth of ER+ patient-derived breast cancer xenograft tumors. ODM-207 was shown to synergize with palbociclib in vitro in ER+ breast cancer cell lines.

ODM-207 targeted several pathways important for cancer progression such as MYC, estrogen response and cell cycle gene signatures.

The combination of ODM-207 and CDK4/6 inhibitor palbociclib achieved greater cell proliferation inhibition than either drug alone at sub IC₅₀ concentrations.

References

Ameratunga M, et al. *Br J Cancer*. 2020 Dec;123(12):1730-1736.

Sun Y, et al. *Front Pharmacol*. 2021 Jan 26;11:621093.

Mäkelä R, et al. *Oncotarget*. 2021 May 25;12(11):1100-1109.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com